<DOC>
	<DOC>NCT01960348</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis</brief_summary>
	<brief_title>APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies, Familial</mesh_term>
	<mesh_term>Amyloidosis, Familial</mesh_term>
	<criteria>Male or female of 18 to 85 years of age (inclusive); Have a diagnosis of FAP Neuropathy Impairment Score requirement of 5130 Meet Karnofsky performance status requirements Have adequate complete blood counts and liver function tests Have adequate cardiac function Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV) Had a prior liver transplant or is planned to undergo liver transplant during the study period; Has untreated hypo or hyperthyroidism; Has known human immunodeficiency virus (HIV) infection; Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated; Recently received an investigational agent or device Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloid Polyneuropathy</keyword>
	<keyword>TTR</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>Amyloidosis</keyword>
</DOC>